Prostate cancer vaccine - CellGenix
Latest Information Update: 10 Aug 2007
At a glance
- Originator CellGenix Technologie Transfer
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 10 Aug 2007 Preclinical development is ongoing
- 06 Dec 2006 Preclinical development is still ongoing
- 02 Oct 2001 Preclinical development for Prostate cancer in Germany (Unknown route)